Bli medlem
Bli medlem

Du är här

2016-05-09

Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases,

Prothena Corporation plc
Press release

Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose
Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory
Diseases, at EULAR 2016

DUBLIN, Ireland, 2016-05-09 22:05 CEST (GLOBE NEWSWIRE) -- Prothena Corporation
plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein immunotherapies,
today announced that clinical data from its Phase 1 single ascending dose study
of PRX003 in healthy volunteers will be highlighted in an oral presentation at
The European League Against Rheumatism Annual European Congress of Rheumatology
(EULAR 2016) to be held June 8-11 in London.

PRX003 is a monoclonal antibody targeting melanoma cell adhesion molecule
(MCAM), believed to be a critical mediator of Th17 cell pathogenesis, for the
potential treatment of inflammatory diseases where multiple cytokines play a
role. PRX003 is designed to address inflammation by targeting Th17 cells
upstream of the process that releases disease-causing cytokines into tissue.

The PRX003 Phase 1 clinical data will be highlighted in the following oral
presentation:

Session #EULAR16-3570, Abstract #OP0205
Clinical and Preclinical Assessment of the Anti-MCAM Monoclonal Antibody
PRX003, a Potential Novel Treatment of Th17-mediated Inflammatory Diseases

-- Presenter: Gene Kinney, PhD, Chief Scientific Officer and Head of Research
and Development, Prothena
-- Session: Novel insights into B and T cell immunity in rheumatic disease
-- Date and Time: Friday, June 10, 2016 11:20 a.m. BST
-- Location: ExCeL London, Room S20

Prothena management plans to discuss the data during an audio webcast and
conference call on June 9, 2016 at 4:30 p.m. ET. Further details on how to
access the discussion will be provided on the day of the webcast.

About MCAM and Inflammatory Disease

Within the immune system, a small population of T cells known as Th17 cells,
initiate the body's response to infections, and are known to be a key
participant in both normal inflammatory reactions as well as pathogenic
autoimmune diseases. MCAM is a cell adhesion molecule expressed on the surface
of Th17 cells, and confers upon these cells the ability to interact with
vasculature and subsequently migrate from circulation into tissues, in some
cases to initiate or perpetuate a disease process. While only two to six
percent of T cells in circulation express MCAM, these cells secrete the Th17
signature cytokines, IL-17A and IL-17F, but can also produce other cytokines
such as such as IFN?, GM-CSF, TNF? and IL-22 that may play a role in disease
pathogenesis.

About PRX003

PRX003 is a monoclonal antibody being developed for the potential treatment of
inflammatory diseases where multiple cytokines play a role, including
psoriasis. PRX003 is designed to occupy and down-regulate MCAM, a cell adhesion
molecule expressed on the surface of Th17 cells, thereby sequestering cells
that secrete disease-causing cytokines in the bloodstream and preventing their
migration into tissues. As MCAM expressing T cells appear to be
disproportionately involved in propagation of inflammation, targeting the T
cell, rather than any individual cytokine, may provide a highly specific way to
impact multiple pathogenic processes, while leaving the vast majority of immune
cells unaffected. PRX003 may be useful for the treatment of a variety of
inflammatory diseases such as psoriasis, psoriatic arthritis, rheumatoid
arthritis, multiple sclerosis, sarcoidosis, uveitis, giant cell arteritis, and
Behcet's disease. For more information about Prothena’s ongoing Phase 1b
clinical study of PRX003 in patients with psoriasis please
visitwww.clinicaltrials.gov and search identifier NCT02630901.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company
seeking to fundamentally change the course of progressive diseases with its
clinical pipeline of novel therapeutic antibodies. Fueled by its deep
scientific understanding built over decades of research in protein misfolding
and cell adhesion – the root causes of many serious or currently untreatable
amyloid and inflammatory diseases – Prothena has advanced several drug
candidates into clinical trials while pursuing discovery of additional novel
therapies. Our clinical pipeline of antibody-based product candidates targets
a number of potential indications including AL amyloidosis (NEOD001),
Parkinson’s disease and other related synucleinopathies (PRX002) and
inflammatory diseases, including psoriasis (PRX003).

Forward-looking Statements

This press release contains forward-looking statements. These statements relate
to, among other things, PRX003’s mechanism of action and potential use as a
treatment for variety of inflammatory diseases. These statements are based on
estimates, projections and assumptions that may prove not to be accurate, and
actual results could differ materially from those anticipated due to known and
unknown risks, uncertainties and other factors, including but not limited to
the risks, uncertainties and other factors described in the "Risk Factors"
sections of our Annual Report on Form 10-K filed with the Securities and
Exchange Commission (SEC) on February 25, 2016 and our subsequent Quarterly
Reports on Form 10-Q filed with the SEC. Prothena undertakes no obligation to
update publicly any forward-looking statements contained in this press release
as a result of new information, future events or changes in Prothena's
expectations.

Contacts:

Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com

Media: Ellen Rose, Head of Communications
650-922-2405, ellen.rose@prothena.com

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.